Primary effusion lymphoma (PEL) is rare subtype of diffuse large B-cell lymphoma (DLBCL). It is also considered a distinct type of non-Hodgkin lymphoma (NHL) in the World Health Organization (WHO) classification system. PEL may also be called body cavity lymphoma.
PEL is linked to human herpes virus 8 (HHV8) infection. It is also associated with Epstein-Barr virus (EBV) infection in many cases. PEL most often occurs in people with weakened immune systems, such as those with HIV/AIDS. It can sometimes occur in people who have had organ transplants.
PEL is a very fast-growing (aggressive) lymphoma. There is often an abnormal buildup of fluid in body cavities, usually in:
Lymphoma cells are found in the fluid in these body cavities.
People with PEL often have a very poor prognosis.
Treatment of PEL is usually chemotherapy.
A combination of chemotherapy drugs is usually used to treat PEL. The same combination used to treat DLBCL is often used.
Rituximab (Rituxan) is a type of biological therapy that is often used for many B-cell types of NHL, but it does not play a role in treating PEL. This is because PEL cells do not usually express CD20, a protein found on several cancerous B cells. Rituximab targets this protein, so it would not be effective in treating PEL.
Highly active antiretroviral therapy (HAART) is a combination of anti-HIV drugs. It is used for treating HIV infection and to reduce the risk of developing AIDS-related diseases. HAART is used in addition to chemotherapy if the person with PEL is HIV positive.
For more detailed information on specific drugs, go to sources of drug information.
We all need our own personal support system, but no matter how good your own personal support system is, it’s not the same as connecting with other survivors.
The Canadian Cancer Society is funding lifesaving clinical trials that give people with cancer access to the newest types of treatment.